Please use this identifier to cite or link to this item:
|Title:||Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas|
Nishimoto, L. N.
Kowalski, L. P.
Miguel, R. E.
Brentani, R. R.
Brentani, M. M.
Universidade Federal de São Paulo (UNIFESP)
Inst Adolfo Lutz Registro
Hosp Canc AC Camargo
Inst Ludwig Pesquisa Canc
head and neck tumors
|Citation:||Cancer Detection and Prevention. Oxford: Elsevier B.V., v. 28, n. 3, p. 178-186, 2004.|
|Abstract:||c-myc and p53 genes were frequently deregulated in head and neck squamous cell carcinoma (HNSCC). To determine if the concomitant expression of the two oncogenes might have prognostic value, the survival and free disease time of 140 consecutive HNSCC patients followed up for a median time of 29.9 months was analyzed in the light of p53 and c-myc expression assessed by immumohistochemistry. Positive c-myc and p53 staining was detected respectively in 35.7 and 50.7% of the tumors. Double positivity emerged in 16.4% of the cases. Overall-survival of patients was not associated with the immunoreactivity of p53 or c-myc considered separately or grouped in subsets. Considering only the advanced stages, the concomitant expression of both oncogenes in tumors was associated with worse disease-free survival (P = 0.004) suggesting a role for p53 and c-myc genes in progression of this HNSCC subset. Clinical parameters (presence of lymph nodes, histologic grade and tumor width) remained important indicators of overall survival (OS). (C) 2004 International Society for Preventive Oncology. Published by Elsevier B.V. All rights reserved.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.